CELLULARLINE SPA (CELL.MI) Fundamental Analysis & Valuation

BIT:CELLIT0005244618

Current stock price

2.225 EUR
+0 (+0.23%)
Last:

This CELL.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CELL.MI Profitability Analysis

1.1 Basic Checks

  • In the past year CELL has reported negative net income.
  • In the past year CELL had a positive cash flow from operations.
  • In multiple years CELL reported negative net income over the last 5 years.
  • Each year in the past 5 years CELL had a positive operating cash flow.
CELL.MI Yearly Net Income VS EBIT VS OCF VS FCFCELL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -20.20%, CELL is not doing good in the industry: 84.85% of the companies in the same industry are doing better.
  • With a Return On Equity value of -36.26%, CELL is not doing good in the industry: 69.70% of the companies in the same industry are doing better.
  • CELL has a Return On Invested Capital (5.01%) which is in line with its industry peers.
  • CELL had an Average Return On Invested Capital over the past 3 years of 2.92%. This is significantly below the industry average of 17.47%.
  • The last Return On Invested Capital (5.01%) for CELL is above the 3 year average (2.92%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -20.2%
ROE -36.26%
ROIC 5.01%
ROA(3y)-5.63%
ROA(5y)-10.63%
ROE(3y)-10.27%
ROE(5y)-18.06%
ROIC(3y)2.92%
ROIC(5y)N/A
CELL.MI Yearly ROA, ROE, ROICCELL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40

1.3 Margins

  • Looking at the Operating Margin, with a value of 3.42%, CELL is doing worse than 60.61% of the companies in the same industry.
  • In the last couple of years the Operating Margin of CELL has grown nicely.
  • The Gross Margin of CELL (40.98%) is better than 60.61% of its industry peers.
  • In the last couple of years the Gross Margin of CELL has remained more or less at the same level.
Industry RankSector Rank
OM 3.42%
PM (TTM) N/A
GM 40.98%
OM growth 3YN/A
OM growth 5Y31.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y-1.18%
CELL.MI Yearly Profit, Operating, Gross MarginsCELL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

7

2. CELL.MI Health Analysis

2.1 Basic Checks

  • CELL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, CELL has less shares outstanding
  • Compared to 5 years ago, CELL has less shares outstanding
  • CELL has a worse debt/assets ratio than last year.
CELL.MI Yearly Shares OutstandingCELL.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
CELL.MI Yearly Total Debt VS Total AssetsCELL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • CELL has an Altman-Z score of 2.93. This is not the best score and indicates that CELL is in the grey zone with still only limited risk for bankruptcy at the moment.
  • CELL's Altman-Z score of 2.93 is fine compared to the rest of the industry. CELL outperforms 69.70% of its industry peers.
  • CELL has a debt to FCF ratio of 2.29. This is a good value and a sign of high solvency as CELL would need 2.29 years to pay back of all of its debts.
  • The Debt to FCF ratio of CELL (2.29) is better than 78.79% of its industry peers.
  • A Debt/Equity ratio of 0.15 indicates that CELL is not too dependend on debt financing.
  • CELL's Debt to Equity ratio of 0.15 is amongst the best of the industry. CELL outperforms 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.29
Altman-Z 2.93
ROIC/WACC0.66
WACC7.64%
CELL.MI Yearly LT Debt VS Equity VS FCFCELL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.20 indicates that CELL has no problem at all paying its short term obligations.
  • CELL has a Current ratio of 2.20. This is amongst the best in the industry. CELL outperforms 84.85% of its industry peers.
  • CELL has a Quick Ratio of 1.53. This is a normal value and indicates that CELL is financially healthy and should not expect problems in meeting its short term obligations.
  • CELL's Quick ratio of 1.53 is amongst the best of the industry. CELL outperforms 84.85% of its industry peers.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.53
CELL.MI Yearly Current Assets VS Current LiabilitesCELL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

3

3. CELL.MI Growth Analysis

3.1 Past

  • CELL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -764.12%.
  • CELL shows a decrease in Revenue. In the last year, the revenue decreased by -3.88%.
  • CELL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.42% yearly.
EPS 1Y (TTM)-764.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-619.22%
Revenue 1Y (TTM)-3.88%
Revenue growth 3Y4.4%
Revenue growth 5Y8.42%
Sales Q2Q%-6.01%

3.2 Future

  • CELL is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.99% yearly.
  • Based on estimates for the next years, CELL will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y0%
EPS Next 2Y2.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.9%
Revenue Next 2Y1.71%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CELL.MI Yearly Revenue VS EstimatesCELL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
CELL.MI Yearly EPS VS EstimatesCELL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6 0.8 1

5

4. CELL.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • CELL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • CELL is valuated cheaply with a Price/Forward Earnings ratio of 6.61.
  • Based on the Price/Forward Earnings ratio, CELL is valued cheaply inside the industry as 87.88% of the companies are valued more expensively.
  • CELL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.12.
Industry RankSector Rank
PE N/A
Fwd PE 6.61
CELL.MI Price Earnings VS Forward Price EarningsCELL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

  • 100.00% of the companies in the same industry are more expensive than CELL, based on the Enterprise Value to EBITDA ratio.
  • CELL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CELL is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.54
EV/EBITDA 0.87
CELL.MI Per share dataCELL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.99%
EPS Next 3YN/A

5

5. CELL.MI Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.72%, CELL is a good candidate for dividend investing.
  • CELL's Dividend Yield is rather good when compared to the industry average which is at 1.04. CELL pays more dividend than 90.91% of the companies in the same industry.
  • CELL's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 4.72%

5.2 History

  • The dividend of CELL decreases each year by -20.42%.
Dividend Growth(5Y)-20.42%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • The earnings of CELL are negative and hence is the payout ratio. CELL will probably not be able to sustain this dividend level.
DP-5.54%
EPS Next 2Y2.99%
EPS Next 3YN/A
CELL.MI Yearly Income VS Free CF VS DividendCELL.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

CELL.MI Fundamentals: All Metrics, Ratios and Statistics

CELLULARLINE SPA

BIT:CELL (4/28/2026, 10:50:22 AM)

2.225

+0 (+0.23%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)03-09
Earnings (Next)05-05
Inst Owners4.94%
Inst Owner ChangeN/A
Ins Owners19.57%
Ins Owner ChangeN/A
Market Cap48.66M
Revenue(TTM)231.79M
Net Income(TTM)-35.05M
Analysts82.86
Price Target3.98 (78.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.72%
Yearly Dividend0.09
Dividend Growth(5Y)-20.42%
DP-5.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.88%
PT rev (3m)-4.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-21.43%
EPS NY rev (3m)-21.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.24%
Revenue NY rev (3m)-4.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.61
P/S 0.21
P/FCF 3.54
P/OCF 2.51
P/B 0.5
P/tB 0.77
EV/EBITDA 0.87
EPS(TTM)-1.68
EYN/A
EPS(NY)0.34
Fwd EY15.13%
FCF(TTM)0.63
FCFY28.22%
OCF(TTM)0.89
OCFY39.82%
SpS10.6
BVpS4.42
TBVpS2.88
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -20.2%
ROE -36.26%
ROCE 6.69%
ROIC 5.01%
ROICexc 6.28%
ROICexgc 9.75%
OM 3.42%
PM (TTM) N/A
GM 40.98%
FCFM 5.92%
ROA(3y)-5.63%
ROA(5y)-10.63%
ROE(3y)-10.27%
ROE(5y)-18.06%
ROIC(3y)2.92%
ROIC(5y)N/A
ROICexc(3y)3.5%
ROICexc(5y)N/A
ROICexgc(3y)7.94%
ROICexgc(5y)N/A
ROCE(3y)3.89%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y44.53%
ROICexc growth 3YN/A
ROICexc growth 5Y73.05%
OM growth 3YN/A
OM growth 5Y31.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y-1.18%
F-Score5
Asset Turnover1.34
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.29
Debt/EBITDA 0.22
Cap/Depr 10.1%
Cap/Sales 2.44%
Interest Coverage 250
Cash Conversion 30.36%
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.53
Altman-Z 2.93
F-Score5
WACC7.64%
ROIC/WACC0.66
Cap/Depr(3y)28.42%
Cap/Depr(5y)23.36%
Cap/Sales(3y)3.31%
Cap/Sales(5y)3.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-764.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-619.22%
EPS Next Y0%
EPS Next 2Y2.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.88%
Revenue growth 3Y4.4%
Revenue growth 5Y8.42%
Sales Q2Q%-6.01%
Revenue Next Year0.9%
Revenue Next 2Y1.71%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.14%
EBIT growth 3YN/A
EBIT growth 5Y43.02%
EBIT Next Year47.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.36%
FCF growth 3Y266.02%
FCF growth 5Y64.61%
OCF growth 1Y-9.99%
OCF growth 3Y58.25%
OCF growth 5Y11.38%

CELLULARLINE SPA / CELL.MI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CELLULARLINE SPA (CELL.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CELL.MI.


What is the valuation status for CELL stock?

ChartMill assigns a valuation rating of 5 / 10 to CELLULARLINE SPA (CELL.MI). This can be considered as Fairly Valued.


How profitable is CELLULARLINE SPA (CELL.MI) stock?

CELLULARLINE SPA (CELL.MI) has a profitability rating of 3 / 10.


How financially healthy is CELLULARLINE SPA?

The financial health rating of CELLULARLINE SPA (CELL.MI) is 7 / 10.


Can you provide the dividend sustainability for CELL stock?

The dividend rating of CELLULARLINE SPA (CELL.MI) is 5 / 10 and the dividend payout ratio is -5.54%.